Avalyn Pharma combines heavy recent insider buying and high modeled upside with quality metrics below the engine's floor, a single extreme earnings miss, and institutional-constraint risk typical of a small, binary-outcome biotech.
Thesis pillars
- Quality Below Engine Floor→Stable
- Heavy Insider Buying↓Deteriorating
- High Modeled Upside↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026· older than 90 days
Avalyn Pharma Inc. (AVLN) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.40: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to... Read more
Sell if holding. Engine safety override at $28.40: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 116d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.
Recent developments
updated Nov 16, 2026Recent Developments — Avalyn Pharma Inc.
Latest news
- NEWS Morgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53 — benzinga Nov 16, 2026 negative
- NEWS Avalyn Pharma Reports Third Quarter 2026 Financial Results and Business Highlights — fiscal.ai Nov 12, 2026
- NEWS Avalyn Pharma Q3 EPS $(0.67) Beats $(0.75) Estimate — benzinga Nov 12, 2026 positive
- NEWS Avalyn Pharma Announces Participation in Upcoming Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday — benzinga Oct 2, 2026 positive
Latest item Nov 16, 2026 · Generated 2026-11-22T12:02:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.40: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $26.41. Score 5.0/10, moderate confidence.
Analyst target: $53.07 (+86.9% upside). Prior stop was $26.41. Stop-loss: $26.41.
Quality below floor (2.5 < 4.0).
Avalyn Pharma Inc. trades at a P/E of N/A (forward -11.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts rate AVLN, with a consensus score of 4.3/5. 5 analysts publish price targets averaging $61.
What does Avalyn Pharma Inc. do?Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare...
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.